EXHIBIT 10.11

                            INDEMNIFICATION AGREEMENT

                            OF JEONG-HYUN LEE, PH.D.

      This Indemnification Agreement (this "AGREEMENT") is made as of July 11,
2005 by Jeong-Hyun Lee, Ph.D., an individual residing in the Republic of Korea
("DR. LEE") to iCurie, Inc., a Nevada corporation (the "COMPANY"):

      A.    I, Dr. Lee, hereby represent that I am the Chief Technology Officer
            ("CTO") of iCurie Lab Holdings, Ltd. (the "UK COMPANY") and
            immediately prior to the Exchange (as defined herein), was a
            majority shareholder in the UK Company.

      B.    I hereby acknowledge the following:

            1.    That as of the date hereof, (i) the Company acquired all the
                  stock of the UK Company from the shareholders thereof
                  (including myself), as more specifically set forth in that
                  certain Share Exchange Agreement by and among the Company, the
                  UK Company and certain additional parties (the "EXCHANGE"),
                  (ii) immediately following the Exchange, I became CTO and a
                  significant shareholder of the Company, and (iii) immediately
                  following the Exchange, the Company will issue for cash up to
                  $15.4 million Preferred A shares (the "OFFERING").

            2.    That I will gain a substantial benefit if the Offering closes.

            3.    That the UK Company owns an 80.2% equity interest in iCurie
                  Lab, Inc., a corporation formed under the laws of the Republic
                  of Korea ("iCurie Korea"), and that I am the Chief Executive
                  Officer of iCurie Korea.

            4.    That I have been the UK Company's sole representative in
                  informal discussions with the minority shareholders of iCurie
                  Korea (the "Minority Shareholders") to purchase their 19.8%
                  equity interests in iCurie Korea (the "Minority Equity").

            5.    That the Company's ability (directly or through the UK
                  Company, its wholly-owned subsidiary following the Exchange)
                  to acquire the Minority Equity is important to closing the
                  Offering.

      C.    Based on the foregoing, I hereby represent and warrant to the
            Company that the Company (directly or through a subsidiary) will be
            able to acquire all of the Minority Equity from the Minority
            Shareholders for no greater than $2,200,000 USD. Furthermore, I
            covenant to the Company that if the purchase price of the Minority
            Equity exceeds $2,200,000 USD, then I will personally indemnify the
            Company for any amount the Company pays in excess of $2,200,000 USD
            to acquire the Minority Interest.



      D.    In furtherance of and as security for the indemnification obligation
            set forth herein, I hereby pledge one million (1,000,000) common
            shares of the Company owned by me as of the date hereof, as more
            fully set forth in the Stock Pledge Agreement set forth as Exhibit
            A.

      E.    I hereby acknowledge that the UK Company and the Company has relied
            and will rely on my representations, warranties, and covenants in
            this Agreement in preparing the Offering materials and closing the
            Offering, and that this Agreement and the indemnifications
            provisions set forth herein are enforceable by law against me. I
            further acknowledge that, but for this Agreement, the Company will
            not make any statements, representations, warranties or covenants to
            the investors about the possibility, probability or feasibility of
            acquiring the Minority Equity, the absence of which would
            significantly affect the Offering.

                                              "DR. LEE"

                                              /s/ Jeong Hyun Lee
                                              ----------------------------------
                                              Jeong-Hyun Lee, Ph.D., personally

                                       2